Follicum AB announced today that the patent which previously (June 22, 2020) received a so-called Notice of Allowance from the US Patent and Trademark Office (“USPTO”) has now also been formally approved by the authority. The patent is called “Peptides for Treatment of Diabetes” and the patent will be valid until 2038.
The patent (US 10815283) covers peptides from the company’s two peptide classes and their use in the treatment of diabetes and its complications. The patent will be formally approved on October 27, 2020.
CEO Jan Alenfall comments:
“The US is by far the largest market for Follicum in diabetes and its complications. This formal patent approval is therefore of great importance to us and an important step in our global patent strategy. We are continuously working to expand our patent portfolio in our key markets.”
Diabetes is rapidly increasing globally. The disease is characterized by poor blood sugar control due to defective insulin signaling, which causes serious sequelae such as cardiovascular disease, renal failure, obesity, blindness and diabetic foot ulcers. Diabetes as well as its accompanying illnesses represents a major burden, partly for the individual patient, but also for the entire health care system. There is thus an already large and growing global need for new therapies that address effective control of glucose levels in combination with preventive effects on the various diabetic complications.
For further information, please contact:
Jan Alenfall – CEO, Follicum AB
Telephone: +46 (0)709 31 51 15
About Follicum AB
Follicum AB (publ) develops drug candidates based on tissue reparing peptides with potential use in several therapeutic areas. The company’s primary candidate, FOL-005 for stimulating hair growth, is currently being evaluated in a phase IIa study in collaboration with internationally reputable specialist clinics. The company’s project in diabetes aims at protecting insulin producing cells against damage and thereby reducing the risk of complications. Based on promising preclinical results preparations for entering a phase I study is ongoing, which expects to be initiated in 2021. Both projects have the potential to become so called first-in-class drugs. For more information, please visit www.follicum.com.